7 Eden Park Drive
Level 5
Macquarie Park, NSW 2113
Australia
61 2 8935 9629
https://www.oncosil.com.au
Secteur(s): Healthcare
Secteur d’activité: Medical Devices
Employés à temps plein:
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Nigel Lange | CEO, MD & Director | 388,26k | S.O. | S.O. |
Mr. Christian Dal Cin | CFO & Company Secretary | S.O. | S.O. | S.O. |
Dr. Ralph Peters | Chief Medical Officer | S.O. | S.O. | S.O. |
Mr. David Turner | Head of Medical Affairs | S.O. | S.O. | S.O. |
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
L’ISS Governance QualityScore de OncoSil Medical Limited en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..